EndoCellutions

What EndoCellutions does

EndoCellutions, Inc. is a privately held medical device company headquartered in Marshfield, Massachusetts, that develops a point-of-care system for preparing bone marrow aspirate concentrate (BMAC) and platelet rich plasma (PRP). Its core offering is a patent-pending cell separator that extracts and concentrates target cells from patient marrow quickly and without disrupting or damaging them, and the system is designed to operate with standard centrifuges rather than proprietary processing equipment. The technology is positioned for use during surgical procedures, where physicians apply concentrated cells directly to the surgical site for regenerative applications.

The company sells its hardware-based system to orthopedic surgeons and regenerative medicine practitioners performing point-of-care procedures, with revenue derived from medical device sales of the cell separation platform and associated consumables. Its go-to-market is described as sales-led and direct-to-physician, supported only by a basic WordPress website that has not been updated with substantive content since December 31, 2011. No public pricing, distribution agreements, regulatory clearances, certifications, customer logos, or partnerships are disclosed, and the only known leadership is CEO Andrew McGillicuddy.

The company has raised approximately $900,056 across two small funding rounds in 2014 and 2017 with undisclosed investors, and operates with 11–50 employees. There is no evidence of subsequent funding events, headcount growth, geographic expansion, or new product development, and the absence of post-2017 disclosures materially limits visibility into current operating status and commercial traction.

Name

EndoCellutions

Legal name

EndoCellutions, Inc.

Website

https://endocellutions.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

EndoCellutions, Inc. is a private medical device company that sells a point-of-care cell separation system for preparing bone marrow aspirate concentrate (BMAC) and platelet rich plasma (PRP) for orthopedic and regenerative medicine physicians.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Medical Devices

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Point-of-care cell separation
• Bone marrow aspirate concentrate
• Platelet rich plasma preparation
• Regenerative medicine devices
• Surgical cell processing

Headquarters

HQ city

Marshfield

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Medical Device Sales: The company generates revenue through the sale of its point-of-care cell separation systems and associated consumables for bone marrow aspirate concentrate and platelet rich plasma preparation.

Go-to-market motion1 record

Marketing channels1 record

Core offering

EndoCellutions develops and sells a point-of-care cell separation system used to prepare bone marrow aspirate concentrate (BMAC) and platelet rich plasma (PRP) for regenerative medicine procedures. The patent-pending cell separator is used with standard centrifuges and enables surgeons to extract, concentrate, and apply targeted cells to surgical sites in a simple, consistent, and non-damaging manner.

Product overview

EndoCellutions offers a single unified point-of-care system for preparing bone marrow aspirate concentrate (BMAC) and platelet rich plasma (PRP). The system provides high yields of concentrated viable cells with consistent cell separation, intuitive processing, and compatibility with standard centrifuges. The patent-pending technology enables physicians to extract, concentrate, and apply targeted cells to surgical sites in a simple, easy-to-use, and consistent manner.

Differentiator

Problem solved

Functional benefit

Products and services

• Point-of-Care BMAC and PRP Preparation System A point-of-care medical device system that uses patent-pending cell separator technology together with a standard centrifuge to extract, concentrate, and apply bone marrow aspirate concentrate (BMAC) and platelet rich plasma (PRP) to surgical sites; designed for orthopedic surgeons and regenerative medicine physicians performing regenerative procedures at the point of care.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves4 records

Expansion highlights2 records

Direct peers

• Arthrex: Arthrex is the dominant orthopedic surgical device company and sells the Arthrex Angel system, a directly comparable point-of-care PRP preparation platform used by the same orthopedic surgeon customer base.
• EmCyte Corporation: EmCyte makes the PureBMC and other BMAC/PRP concentration systems targeting exactly the same point-of-care orthopedic and regenerative medicine use cases EndoCellutions serves.
• Terumo Blood and Cell Technologies: Terumo BCT (via the legacy Harvest SmartPrep line) sells point-of-care cell separation devices for BMAC and PRP, making it one of the closest direct functional competitors in this niche.
• Isto Biologics: Isto Biologics produces point-of-care bone marrow concentration kits and orthobiologic products aimed at the same spine and orthopedic surgeons preparing BMAC at the time of surgery.
• Royal Biologics: Royal Biologics is a regenerative medicine company offering autologous biologic preparations (including PRP and BMAC kits) for orthopedic applications, overlapping with EndoCellutions' surgical workflow.
• Vivex Biologics: Vivex Biologics develops and markets cell and tissue-based therapies including amniotic and orthobiologic products used in the same regenerative orthopedic settings the company targets.

Emerging players

• Cesca Therapeutics (now known as ThermoGenesis / Plus Therapeutics lineage): Cesca/ThermoGenesis historically developed automated point-of-care cell separation and cell processing systems for BMAC and related therapies, making it a functional and historical analog of EndoCellutions' device approach.

Broad incumbents

• Exactech: Exactech is a broad orthopedic implant and biologics company with an orthobiologics portfolio reaching the same surgeon base, though not exclusively focused on point-of-care cell separation.
• Orthofix: Orthofix is a diversified orthopedic device company with biologics spine and extremity offerings, selling into the same surgical call points as EndoCellutions' target users.
• Stryker: Stryker is a leading broad-line orthopedic and surgical device incumbent with growing presence in regenerative and sports medicine adjacencies relevant to EndoCellutions' physician customers.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EndoCellutions